Tirbanibulin Alters Oncogenic Pathways in HPV-18 HeLa Cells

Tirbanibulin is best known as a topical treatment for actinic keratosis (AK), but its cellular effects may extend beyond the indication for which its ointment is used. In a 2024 study, Moore and colleagues tested tirbanibulin in HeLa cells containing integrated human papillomavirus type 18 (HPV-18), examining both cell proliferation and proteins linked to viral oncogenesis and tumor-associated signaling. The work offers a focused cellular investigation of how tirbanibulin may affect HPV oncoproteins, while leaving important questions about mechanism and clinical relevance open.

Study Background and Research Question

Tirbanibulin 1% ointment is an antiproliferative treatment approved for AK. The authors note prior clinical reports of lesion regression in several HPV-associated conditions, including HPV-positive squamous cell carcinoma and vulvar high-grade squamous intraepithelial lesions. These observations motivated a mechanistic question: could tirbanibulin alter HPV oncoprotein expression, as well as cellular pathways that support proliferation and transformation?

The study focused on HeLa cells, a human cervical cancer line with integrated HPV-18. HPV E6 and E7 proteins are central to HPV-associated cellular transformation, and their abundance is influenced by host-cell regulatory processes. The authors examined whether tirbanibulin-associated changes in Src-related signaling might coincide with changes in E6 and E7 and with downstream markers of cell-cycle regulation, survival, and invasion. The reference study therefore connects an established antiproliferative compound with a specific HPV-positive cellular context; it does not test whether the drug clears infection or treats HPV disease in patients.

Key Innovation from the Reference Study

The central contribution is the coordinated measurement of proliferation and a panel of pathway-associated proteins in HPV-18-positive cells. Earlier work on tirbanibulin has emphasized Src inhibition and disruption of tubulin polymerization. Here, the investigators asked whether protein changes associated with Src signaling could also relate to HPV E6 and E7 expression and to cellular phenotypes relevant to tumor growth.

The proposed interpretation is that tirbanibulin may influence an Src–MEK–ERK signaling route and downstream SP1 activity, thereby contributing to reduced E6 and E7 protein expression. This is a mechanistic hypothesis supported by the observed pattern of protein changes, not proof that every step in the pathway is directly inhibited by tirbanibulin. In particular, the study reports protein abundance and phosphorylation markers; the findings should not be read as direct demonstration of altered viral transcription or direct binding to each pathway component.

This distinction helps place the paper alongside broader descriptions of tirbanibulin as a dual Src and tubulin inhibitor. For a wider overview of those established pharmacological themes, see the related discussion of dual Src and tubulin inhibition. The HeLa study adds a different layer: it investigates how treatment-associated protein patterns appear in an HPV-18-containing cancer-cell model.

Methods and Experimental Design Insights

The investigators exposed HeLa cells to increasing concentrations of tirbanibulin and measured cell proliferation to estimate an inhibitory concentration. They also used immunoblotting with antibodies directed at proteins in the canonical Src pathway, HPV-18 E6 and E7 regulation, apoptosis, and invasion or metastasis-associated signaling. This design links a functional cell-growth readout with molecular measurements, allowing the authors to assess whether changes in proliferation occur alongside changes in selected proteins.

The reported half-maximal inhibitory concentration (IC₅₀) for HeLa-cell proliferation was 31.49 nmol/L. Immunoblot targets included Src and phospho-Src, Ras, c-Raf, ERK proteins and their phosphorylated forms, Mnk1, eIF4E, E6, E7, retinoblastoma protein (Rb), MDM2, E2F1, focal adhesion kinase (FAK), p130Cas, Mcl-1, Bcl-2, and PARP forms associated with apoptosis. The article reports statistically significant changes for these selected endpoints, as detailed in the published report.

Protocol Parameters

• Cell model: The study used HeLa cells containing integrated HPV-18; this is the literature-reported model, not a general proxy for every HPV genotype or tissue.
• Proliferation benchmark: The reported HeLa-cell IC₅₀ was 31.49 nmol/L. Treat this as a study-specific reference point, not a universal working concentration or a clinical exposure target.
• Protein readouts: The paper assessed pathway proteins by immunoblotting, including total and phosphorylated Src/ERK-associated targets and markers linked to HPV proteins, apoptosis, and invasion.
• Workflow suggestion: When adapting the assay, use a concentration series that brackets the cell-specific response, and include appropriate vehicle and untreated controls. These are general design recommendations; they should not be mistaken for unreported experimental settings from the paper.
• Interpretation suggestion: Pair protein abundance measurements with orthogonal readouts of viability and, where the research question requires it, direct measurements of viral transcripts or pathway activity. This can help distinguish correlated protein changes from causal pathway effects.

Core Findings and Why They Matter

Tirbanibulin treatment was associated with reduced expression of multiple proteins linked to oncogenic signaling. The authors reported decreases in Src and phospho-Src, Ras, c-Raf, ERK1, phosphorylated ERK1 and ERK2, phospho-Mnk1, and total and phosphorylated eIF4E. This pattern is consistent with suppression of signaling nodes associated with cell growth and protein translation. It supports further study of Src-related signaling in this model, but does not by itself establish which changes are primary drug effects and which occur downstream of reduced proliferation or cellular stress.

The study also found lower E6 and E7 protein expression, alongside changes in Rb, phospho-Rb, MDM2, and E2F1. These proteins are relevant to cell-cycle control and HPV-associated transformation. The findings raise the possibility that tirbanibulin treatment could affect viral oncoprotein abundance through host signaling pathways. However, because the experiments measured protein expression in a single cell line, they do not establish that tirbanibulin directly suppresses HPV gene transcription or that the same response occurs in other HPV types.

Markers associated with adhesion and invasion also changed: phospho-FAK and phospho-p130Cas were reduced. The anti-apoptotic proteins Mcl-1 and Bcl-2 decreased, while cleaved PARP (cPARP) and the cPARP/full-length PARP ratio increased. Taken together, these results are consistent with reduced survival-associated signaling and greater apoptotic activity under the tested conditions. They provide a molecular context for the antiproliferative result, but the reported protein profile should not be equated with a complete characterization of cell death or metastatic behavior.

The practical importance is therefore twofold. First, the study identifies HPV E6 and E7 among the proteins that change with tirbanibulin exposure in an HPV-18-positive model. Second, it places those changes within a broader pattern involving Src-associated signaling, cell-cycle proteins, and apoptosis markers. This makes the paper useful for generating testable hypotheses about an anticancer agent targeting Src kinase in HPV-containing cells, while keeping the evidence at the level of an in vitro mechanistic study.

Comparison with Existing Internal Articles

The linked overview of dual Src and tubulin inhibition emphasizes tirbanibulin’s pharmacological background. Moore and colleagues address a more specific biological question: whether treatment changes proliferation and selected protein pathways in HPV-18-containing HeLa cells. These perspectives are complementary but not interchangeable. The broader pharmacology provides context for why cellular signaling might be affected, whereas the HeLa study supplies model-specific observations about E6, E7, and associated proteins. Neither alone establishes the clinical effectiveness of tirbanibulin for HPV-associated lesions.

Limitations and Transferability

The principal limitation is the use of one HPV-18-containing cell line. HPV-associated disease spans multiple viral genotypes, epithelial sites, and cellular contexts, so results in HeLa cells cannot be assumed to generalize to HPV-positive skin lesions, vulvar disease, or other cancers. The study is also an in vitro experiment and does not determine whether the concentrations and exposure conditions that affect cultured cells can be achieved safely in affected tissues.

Mechanistic interpretation requires caution as well. A set of immunoblot changes can support a pathway model, but it does not establish causality among Src signaling, E6/E7 expression, and cell death. The study’s proposed Src–MEK–ERK–SP1 connection would benefit from experiments that directly test pathway dependence and distinguish changes in viral transcript abundance from changes in protein stability. Replication in additional HPV-positive models and appropriate non-HPV comparators would also help clarify specificity.

Finally, prior clinical reports of lesion regression provide rationale for further investigation, not confirmation that the HeLa-cell mechanism explains those outcomes. The paper itself calls for additional in vitro work and randomized, double-blinded clinical trials in HPV-related disease. Until such evidence is available, tirbanibulin should be described as a candidate for mechanistic and translational research in this setting, not as an established HPV-directed therapy.

Research Support Resources

For researchers adapting related cell-based workflows, KX2-391 dihydrochloride, also known as Tirbanibulin dihydrochloride (SKU A3535), is available as a research reagent. The compound form used in an experiment should be distinguished from the approved topical ointment, and the HeLa study’s findings should be independently validated in each model and assay.